Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Teruhiko Kamiya"'
Autor:
Hisao Imai, Yukiyoshi Fujita, Eriko Hiruta, Takashi Masuno, Shigeki Yamazaki, Hajime Tanaka, Teruhiko Kamiya, Mitsuru Sandoh, Satoshi Takei, Kazuya Arai, Hiromi Nishiba, Junnosuke Mogi, Kyoichi Kaira, Koichi Minato
Publikováno v:
Thoracic Cancer, Vol 13, Iss 16, Pp 2301-2308 (2022)
Abstract Background We conducted a multicenter, retrospective study on the efficacy and safety of naldemedine in thoracic cancer patients using opioids in clinical practice. Methods We retrospectively evaluated thoracic cancer patients treated with n
Externí odkaz:
https://doaj.org/article/421afbce18df4ab5a0851a7fff3ca595
Autor:
Teruhiko Kamiya, Hisao Imai, Yukiyoshi Fujita, Eriko Hiruta, Takashi Masuno, Shigeki Yamazaki, Hajime Tanaka, Mitsuru Sandoh, Satoshi Takei, Kazuya Arai, Hiromi Nishiba, Junnosuke Mogi, Shiro Koizuka, Taeko Saito, Kyoko Obayashi, Kyoichi Kaira, Koichi Minato
Publikováno v:
Medicina, Vol 59, Iss 3, p 492 (2023)
Background and Objectives: Opioid analgesics, which are used for cancer-related pain management, cause opioid-induced constipation (OIC). Naldemedine, a peripheral opioid receptor antagonist, is an OIC-modifying agent, but no focused efficacy and saf
Externí odkaz:
https://doaj.org/article/ffaa96cbed244667b17832d5412fcaa6
Autor:
Eriko Hiruta, Yukiyoshi Fujita, Hisao Imai, Takashi Masuno, Shigeki Yamazaki, Hajime Tanaka, Teruhiko Kamiya, Masako Ito, Satoshi Takei, Masato Matsuura, Hiromi Nishiba, Junnosuke Mogi, Mie Kotake, Shiro Koizuka, Koichi Minato
Publikováno v:
Medicina, Vol 57, Iss 11, p 1233 (2021)
Background and Objectives: Naldemedine is a peripherally acting μ-opioid receptor antagonist that improves opioid-induced constipation. Although clinical trials have excluded patients with poor performance status (PS) and those started on naldemedin
Externí odkaz:
https://doaj.org/article/9baf8d2664d2432e9483df6b1bc9fe63
Autor:
Yukiyoshi Fujita, Hisao Imai, Eriko Hiruta, Takashi Masuno, Shigeki Yamazaki, Hajime Tanaka, Teruhiko Kamiya, Mitsuru Sandoh, Satoshi Takei, Kazuya Arai, Hiromi Nishiba, Junnosuke Mogi, Shiro Koizuka, Taeko Saito, Kyoko Obayashi, Kyoichi Kaira, Koichi Minato
Publikováno v:
Journal of Palliative Medicine. 26:548-553
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::69cf78f12569b665cd1e04fdb18d3db0
https://doi.org/10.1089/jpm.2022.0495
https://doi.org/10.1089/jpm.2022.0495
Autor:
Hiromi Nishiba, Hisao Imai, Yukiyoshi Fujita, Eriko Hiruta, Takashi Masuno, Shigeki Yamazaki, Hajime Tanaka, Teruhiko Kamiya, Masako Ito, Satoshi Takei, Masato Matsuura, Junnosuke Mogi, Kyoko Obayashi, Koichi Minato
Publikováno v:
Annals of Palliative Medicine.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::30dfe61b73b62686c70c176b33a77587
https://doi.org/10.21037/apm-22-1130
https://doi.org/10.21037/apm-22-1130
Autor:
Hiromi Nishiba, Hisao Imai, Yukiyoshi Fujita, Eriko Hiruta, Takashi Masuno, Shigeki Yamazaki, Hajime Tanaka, Teruhiko Kamiya, Masako Ito, Satoshi Takei, Masato Matsuura, Junnosuke Mogi, Koichi Minato, Kyoko Obayashi
Publikováno v:
Journal of Clinical Medicine; Volume 11; Issue 9; Pages: 2672
The efficacy and safety of naldemedine for opioid-induced constipation in patients with cancer has not been investigated in clinical practice. We conducted a multicenter, retrospective study to assess the effects of naldemedine among 10 Japanese inst
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d091286236d724f50b1e70a4b234083
https://doi.org/10.3390/jcm11092672
https://doi.org/10.3390/jcm11092672
Autor:
Hajime Tanaka, Hisao Imai, Teruhiko Kamiya, Satoshi Takei, Shigeki Yamazaki, Mie Kotake, Masato Matsuura, Yukiyoshi Fujita, Masako Ito, Junnosuke Mogi, Shiro Koizuka, Takashi Masuno, Eriko Hiruta, Koichi Minato, Hiromi Nishiba
Publikováno v:
Medicina
Volume 57
Issue 11
Medicina, Vol 57, Iss 1233, p 1233 (2021)
Volume 57
Issue 11
Medicina, Vol 57, Iss 1233, p 1233 (2021)
Background and Objectives: Naldemedine is a peripherally acting μ-opioid receptor antagonist that improves opioid-induced constipation. Although clinical trials have excluded patients with poor performance status (PS) and those started on naldemedin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d666c6bb4268e6af5f01c3c9601d3f02
https://doi.org/10.3390/medicina57111233
https://doi.org/10.3390/medicina57111233